AI Biotechnology LLC - May 21, 2025 Form 3 Insider Report for Zura Bio Ltd (ZURA)

Role: 10%+ Owner
Signature: /s/ Alejandro Moreno for AI Biotechnology LLC
Stock symbol: ZURA
Transactions as of: May 21, 2025
Transactions value $: $0
Form type: 3
Date filed: 5/28/2025, 04:14 PM
Previous filing: Nov 13, 2023
SEC: View on sec.gov

Reporting Owners (4)

Name	Relationship	Address	Signature	Signature date	CIK
AI Biotechnology LLC	10%+ Owner	C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK	/s/ Alejandro Moreno for AI Biotechnology LLC	2025-05-28	0001942670
Access Industries Holdings LLC	10%+ Owner	C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FL, NEW YORK	/s/ Alejandro Moreno for Access Industries Holdings LLC	2025-05-28	0001391297
ACCESS INDUSTRIES MANAGEMENT, LLC	10%+ Owner	C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK	/s/ Alejandro Moreno for Access Industries Management, LLC	2025-05-28	0001508226
Blavatnik Len	10%+ Owner	C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FL, NEW YORK	/s/ Alejandro Moreno as Attorney-in-Fact for Mr. Blavatnik	2025-05-28	0001326628

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ZURA	Class A Ordinary Shares						4.55M	May 21, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ZURA	Warrant (right to buy)							May 21, 2025	Class A Ordinary Shares	13.1M	$0.00	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The securities reported are held directly by AI Biotechnology LLC ("AIB") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AIB. Each of AIH, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.
F2	Each whole pre-funded warrant entitles AIB to purchase one Class A Ordinary Share at an exercise price equal to $0.001 per share, and may be exercised at any time or times on or after the date of issuance, subject to the Beneficial Ownership Blocker (as defined herein). The pre-funded warrants are not exercisable to the extent that the aggregate number of Class A Ordinary Shares beneficially owned by AIB immediately following such exercise would exceed 9.99% of the Class A Ordinary Shares outstanding, as calculated under Rule 13d-3 of the Securities Exchange Act of 1934, as amended; provided, however, that AIB may increase or decrease the beneficial ownership limitation by giving notice to the Issuer (such notice not to be effective until the sixty-first day after the notice is delivered to the Issuer), but not to exceed any percentage in excess of 19.99% (such limitations, the "Beneficial Ownership Blocker").

Content

The securities reported are held directly by AI Biotechnology LLC ("AIB") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AIB. Each of AIH, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

Each whole pre-funded warrant entitles AIB to purchase one Class A Ordinary Share at an exercise price equal to $0.001 per share, and may be exercised at any time or times on or after the date of issuance, subject to the Beneficial Ownership Blocker (as defined herein). The pre-funded warrants are not exercisable to the extent that the aggregate number of Class A Ordinary Shares beneficially owned by AIB immediately following such exercise would exceed 9.99% of the Class A Ordinary Shares outstanding, as calculated under Rule 13d-3 of the Securities Exchange Act of 1934, as amended; provided, however, that AIB may increase or decrease the beneficial ownership limitation by giving notice to the Issuer (such notice not to be effective until the sixty-first day after the notice is delivered to the Issuer), but not to exceed any percentage in excess of 19.99% (such limitations, the "Beneficial Ownership Blocker").

Remarks:

Exhibit List: Ex.24 - Power of Attorney